絞り込み

16644

広告

Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysis.

著者 Flacco ME , Manzoli L , Rosso A , Marzuillo C , Bergamini M , Stefanati A , Cultrera R , Villari P , Ricciardi W , Ioannidis JPA , Contopoulos-Ioannidis DG
Lancet Infect Dis.2018 Jan 19 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (5view , 0users)

Full Text Sources

Miscellaneous

The multicomponent meningococcal serogroup B vaccine (4CMenB) has been licensed in more than 35 countries. However, uncertainties remain about the lowest number of doses required to induce satisfactory, persistent immune responses. We did a systematic review and meta-analysis to provide quantitative estimates for the immunogenicity, persistence of immunogenicity, and safety of 4CMenB vaccine in children and adolescents.
PMID: 29371070 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード